Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Mylan gets ex-US rights to Pulmatrix's Phase II COPD compound

Executive Summary

On the same day it officially merged with Ruthigen and began trading on Nasdaq, Pulmatrix Inc. licensed Mylan NV ex-US development rights to PUR0200, a Phase II bronchodilator for chronic obstructive pulmonary disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register